Marwan Q AL-Samarraie
, Mohammed Ahmed Mustafa
, Marwa T. Ahmed
1,2-Department of Pathological Analysis, College of Applied Sciences, University of Samarra, Iraq
2Department of Medical Laboratory Techniques College of Technology, University of Imam Jafar Al-Sadiq Dujail
3–Department of Microbiology, College of Medicine, University of Tikrit, Iraq
marwan.walady@uosamarra.edu.iq,mohammed.alsad3@gmail.com
Article History: Received: Nov 17, 2020 / Revised: Dec 19, 2020/ Accepted: Dec 25, 2020
Abstract
It is an infectious disease caused by one of Coronavirus. The virus has been named; severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). The first emerge of the virus was in December 2019, in Wuhan China. After that, the infection started to extend to many other countries that by the beginning of 2020 WHO announced that the infection is a worldwide pandemic. The disease has about 2-3% mortality rate has killed nearly one and a half million so far. The WHO, CNHC, and the USN IH have published some recommended treatments for hospitalized patients with Covid-19. Remdesivir, Baricitinib, Pamlanifemab, and Dexamethasone have mostly approved drugs to be used in treatment for hospitalized patients to reduce the time of recovery, but they have not proved effective in reducing mortality.
Keywords Covid-19, Coronavirus, Dexamethasone, Baricitinib, and Remdesivir
How to cite this article
Q AL-Samarraie, M., Mustafa, M. A. and Ahmed, M. T. (2020) Management and Treatment of COVID-19. Science Archives, 1 (3), 174-176. http://dx.doi.org/10.47587/SA.2020.1316
Crossref DOI
http://dx.doi.org/10.47587/SA.2020.1316
Copyright
This is an open-access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation” . European Medicines Agency (EMA) (Press release). 18 September 2020. Retrieved 21 September 2020. Text was copied from this source which is European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020). Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. The Journal of Infection.
ECDPC. (2010). European Centre for Disease Prevention and Control. Retrieved 6 December 2020.
Hoang, T. N., Pino, M., Boddapati, A. K., Viox, E. G., Starke, C. E., Upadhyay, A. A., … & Tharp, G. K. (2020). Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Biorxiv.
Liu, K., Fang, Y. Y., Deng, Y., Liu, W., Wang, M. F., Ma, J. P., … & Li, G. C. (2020). Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese medical journal. 133 (9): 1025–1031. doi:10.1097/CM9.000000000000074 PMC 7147277 . PMID 32044814 .
“COVID-19 (coronavirus): Long-term effects”. Mayo Clinic. Retrieved 8 September 2020.
National Institutes of Health. (2020). COVID-19 treatment guidelines. Bethesda, MD: (https://www .covid19treatmentguidelines .nih .gov/ dexamethasone/ ). Copyright © 2020 Massachusetts Medical Society.
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., & Stebbing, J. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England), 395(10223), e30.
Sims, J. T., Krishnan, V., Chang, C. Y., Engle, S. M., Casalini, G., Rodgers, G. H., … & Higgs, R. E. (2020). Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. Journal of Allergy and Clinical Immunology.
Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., … & Tan, Y. J. (2020). Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients. EMBO Molecular Medicine.
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020). COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases, 20(4), 400-402.
Whitty C. (2020). Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals. London: Medicines and Healthcare Products Regulatory Agency. (https://www .cas .mhra .gov .uk/ ViewandAcknowledgment/ ViewAlert .aspx?AlertID=103054).
Yelin, D., Wirtheim, E., Vetter, P., Kalil, A. C., Bruchfeld, J., Runold, M., … & Bandera, A. (2020). Long-term consequences of COVID-19: research needs. The Lancet Infectious Diseases, 20(10), 1115-1117.
Zuckerman, A. J. (2009). Principles and practice of clinical virology. John Wiley & Sons.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
